NMRA-215

NMRA-215 is an investigational, highly brain-penetrant small molecule inhibitor of the NLRP3 inflammasome, developed by Neumora Therapeutics. It is being prioritized for obesity as its lead indication, with potential relevance to Parkinson’s disease. Preclinical models have shown best-in-class brain penetration, target engagement, and pharmacodynamic activity. The compound is entering clinical development, with first-in-human trials expected to start in early 2026. Its mechanism centers on modulating the innate immune pathway upstream of inflammation, potentially offering benefit for obesity and other neurologic/metabolic disorders where NLRP3 plays a role.